Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Clinical trials play a critical role in developing new medicines, but children are often underrepresented in research. Learn …
As Germany did recently, EU member states should consider joining Belgium, Greece, Spain and the United Kingdom in taking ste…
CSL explains how donated plasma becomes medicine for those with rare, life-threatening conditions.
CSL, which is researching a potential new treatment, interviewed patients living with hereditary hemochromatosis – a metaboli…
Now that bleeding disorders are recognized as a global health priority, countries have an opportunity to make a difference fo…
CSL’s scientists are investigating unanswered questions in search of promising new treatment options. We wanted to know: What…
Exploring two approaches to pain crises
For decades, the rare disease Hereditary Angioedema (HAE) overwhelmed Melissa’s days. But today she’s making up for lost time…
Makiko Matsuyama, president of Japan’s Hereditary Angioedema (HAE) patient association, discusses the danger of undiagnosed H…
